SCHEMBL165468

SCHEMBL165468

O=C(Nc1cccc(Cl)c1)c1cc(C(F)(F)F)c(CN2CCOCC2)cc1OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 5/20 0.59
MET P08581 3/20 0.53
PTGER1 P34995 1/20 0.49
RXFP1 Q9HBX9 1/20 0.47
HTT P42858 1/20 0.47
RECQL P46063 1/20 0.47
TRPV4 Q9HBA0 1/20 0.46
KCNH2 Q12809 2/20 0.46
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
TP53 P04637 1/20 0.45
PPIA P62937 1/20 0.45
CYP3A4 P08684 1/20 0.44
SLCO1B1 Q9Y6L6 1/20 0.44
THRB P10828 1/20 0.44
ABL1 P00519 1/20 0.44
GAA P10253 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167899 0.91 MET (0.54) LRRK2METPTGER1RXFP1KCNH2
SCHEMBL168123 0.88 LRRK2 (0.60) LRRK2METPTGER1HTTRECQL
SCHEMBL167994 0.86 LRRK2 (0.60) LRRK2METCYP3A4SLCO1B1
SCHEMBL257184 0.85 LRRK2 (0.64) LRRK2KCNH2CYP3A4SLCO1B1
SCHEMBL167180 0.83 PTGER1 (0.45) PTGER1HTTRECQLSMN1; SMN2TP53
SCHEMBL168763 0.82 HCRTR1 (0.46) PTGER1HTTRECQLKCNH2SMN1; SMN2
SCHEMBL168574 0.82 MET (0.51) LRRK2METPTGER1HTTRECQL
SCHEMBL257054 0.78 LRRK2 (0.58) LRRK2METHTTNPC1RAB9A
SCHEMBL256458 0.78 LRRK2 (0.62) LRRK2MET
SCHEMBL257191 0.76 LRRK2 (0.63) LRRK2KCNH2CYP3A4SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP claimed
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
US-9365551-B2 2-(benzyloxy) benzamides as LRRK2 kinase inhibitors GLAXO GROUP LIMITED (GB) 2016-06-14 US disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
EP-2611772-B1 2-(BENZYLOXY)BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2014-09-24 EP disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-08-29 US disclosed
EP-2611772-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-10 EP disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed
WO-2012028629-A1 2 - (BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225584-A1 2-(BENZYLOXY) BENZAMIDES AS LRRK2 KINASE INHIBITORS LRRK2, PARK7, BRSK2 LRRK2 1/4885MET 3646/4885PTGER1 4158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.